Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q1 2026 · 10-Q
Revenue$64.86M$64.86M+223.6% vs Q1 2025 Net Income-$42.67M-$42.67MN/M vs Q1 2025 EPS Diluted-$0.48-$0.48N/M vs Q1 2025 Operating Income-$34,202,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
Margins · derivedOperating margin-52.7%+365.2 pt vs Q1 2025
Net margin-65.8%+357.6 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 30, 2026 · 30 d after period end